Myers Amanda, Ristau Benjamin, Mossanen Matthew, Tyson Mark D, Chisolm Stephanie, Sloan Frank, Ball Colleen T, Smith Angela, Lyon Timothy D
Department of Urology, MD Anderson Cancer Center, Houston, TX.
Division of Urology, UConn Health, Farmington, CT.
Urol Oncol. 2024 Feb;42(2):29.e17-29.e22. doi: 10.1016/j.urolonc.2023.09.006. Epub 2023 Nov 22.
To quantify patient reported treatment burden while receiving intravesical therapy for bladder cancer and to survey patient perspectives on in-home intravesical therapy.
We conducted a cross-sectional survey of the Bladder Cancer Advocacy Network Patient Survey Network. Survey questions were developed by investigators, then iteratively revised by clinician and patient advocates. Eligible participants had to have received at least 1 dose of intravesical therapy delivered in an ambulatory setting.
Two hundred thirty-three patients responded to the survey with median age of 70 years (range 33-88 years). Two-thirds of respondents (66%, 151/232) had received greater than 12 bladder instillations. A travel time of >30 minutes to an intravesical treatment facility was reported by 55% (126/231) of respondents. Fifty-six percent (128/232) brought caregivers to their appointments, and 36% (82/230) missed work to receive treatment. Sixty-one respondents (26%) felt the process of receiving bladder instillations adversely affected their ability to perform regular daily activities. Among those surveyed, 72% (168/232) reported openness to receiving in-home intravesical instillations and 54% (122/228) answered that in-home instillations would make the treatment process less disruptive to their lives.
Bladder cancer patients reported considerable travel distances, time requirements, and need for caregiver support when receiving intravesical therapy. Nearly three-quarters of survey respondents reported openness to receiving intravesical instillations in their home, with many identifying potential benefits for home over clinic-based therapy.
量化膀胱癌患者接受膀胱内治疗时报告的治疗负担，并调查患者对家庭膀胱内治疗的看法。
我们对膀胱癌倡导网络患者调查网络进行了横断面调查。调查问卷由研究人员制定，然后由临床医生和患者倡导者反复修订。符合条件的参与者必须在门诊环境中接受过至少1剂膀胱内治疗。
233名患者对调查做出了回应，中位年龄为70岁（范围33 - 88岁）。三分之二的受访者（66%，151/232）接受过超过12次膀胱灌注。55%（126/231）的受访者报告前往膀胱内治疗机构的行程时间超过30分钟。56%（128/232）的受访者带护理人员一同就诊，36%（82/230）的受访者因接受治疗而误工。61名受访者（26%）认为接受膀胱灌注的过程对他们进行日常活动的能力产生了不利影响。在接受调查的人中，72%（168/232）表示愿意接受家庭膀胱内灌注，54%（122/228）回答家庭灌注会使治疗过程对他们生活的干扰更小。
膀胱癌患者报告在接受膀胱内治疗时出行距离较远、时间需求大，且需要护理人员的支持。近四分之三的受访者表示愿意在家中接受膀胱内灌注，许多人认为家庭治疗相对于门诊治疗有潜在益处。
